RE:RE:RE:RE:RE:RE:In closing...Based on the earnings call and what RDW stated as their competitors. By all measures, TLT definitely has a higher duration % rate than the competitors. Here are the results.
| | Theralase | Valrubicin | KEYTRUDA | ADSTILADRIN | BCG plus N-803 | Slow-release Gemcitabine | Creto | Non-viral Gene Therapy |
| Initial Complete Response (%) | 63.00 | 21.00 | 41.00 | 51.00 | 62.00 | 83.00 | 75.00 | 73.00 | |
| Total Response (%) | 71.00 | | | | | | | | |
| Complete Response at 450 Days (%) | 44.00 | 7.70 | 19.00 | 23.50 | 36.00 | 21.00 | 37.00 | | |
| Total Response at 450 Days (%) | 46.00 | | | | | | | | |
| 1-Year Duration (%) | 48.30 | | | | | | | | |
| 2-Year Duration (%) | 42.30 | 4.00 | 9.00 | 19.00 | 25.00 | 5.00 | | | |
| 3-Year Duration (%) | 33.80 | | | | | | | | |